Home > Boards > US Listed > Medical - Equipment > CUTERA, INC. (CUTR)

Introducing Pearl Fractional

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Soapy Bubbles Member Profile
 
Followed By 506
Posts 41,211
Boards Moderated 22
Alias Born 09/16/07
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2019 4:26:11 PM
Cutera Reports Third Quarter 2019 Financial Results Business Wire - 11/7/2019 4:05:00 PM
Cutera, Inc. to Announce Third Quarter 2019 Results Business Wire - 10/22/2019 4:05:00 PM
Cutera Receives Additional Approval from Health Canada for its truSculpt® iD Body Sculpting Technology Business Wire - 9/12/2019 4:00:00 PM
Cutera to Present at Upcoming Investor Conferences Business Wire - 9/9/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 5:27:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2019 4:26:16 PM
Cutera Announces Planned Retirement of David B. Apfelberg, M.D., as Member of the Board of Directors Business Wire - 8/12/2019 4:05:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/8/2019 4:30:57 PM
Cutera Reports Second Quarter 2019 Financial Results Business Wire - 8/8/2019 4:05:00 PM
Cutera Receives ANVISA Approval of truSculpt® Body Sculpting Systems in Brazil Business Wire - 7/23/2019 8:00:00 PM
A Cutera recebe aprovação da ANVISA para os equipamentos de modelagem corporal truSculpt® no Brasil Business Wire - 7/23/2019 8:00:00 PM
Cutera, Inc. to Announce Second Quarter 2019 Results Business Wire - 7/22/2019 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/10/2019 4:21:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/10/2019 4:21:14 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/10/2019 4:20:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/10/2019 6:04:05 AM
Cutera Announces Appointment of David Mowry as Chief Executive Officer Business Wire - 7/9/2019 8:30:00 AM
Cutera Redefines the Muscle Sculpting Market with US Commercial Launch of truSculpt® flex Business Wire - 6/26/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/20/2019 12:49:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 7:50:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 7:48:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 7:46:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 7:44:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 6:04:12 PM
Soapy Bubbles   Tuesday, 10/21/08 02:21:19 PM
Re: None
Post # of 19 
Introducing Pearl Fractional
The fractional ablative laser perfected for photoaging.
What is the Pearl Fractional laser?
The Pearl Fractional laser aggressively treats the signs of photoaging in addition to a broad range of dermal imperfections. Long term improvement may be achieved with a single treatment and patients typically experience only one week of downtime.

Engineered to improve upon current fractional ablative products, Cutera's proprietary YSGG 2790 nm wavelength is unique in the category as it optimizes the ratio of ablation to coagulation. Pearl Fractional removes tissue through a series of microcolumns, while simultaneously stimulating new collagen growth through a controlled zone of thermal coagulation.

Clinical Rationale
Traditionally, fine lines have been improved or eliminated through non-ablative or minimally invasive resurfacing procedures. However, there is a marked clinical need for a short downtime approach to treat diffuse facial photoaging, and/or cosmetic units, such as the upper lip and periorbital areas. Pearl Fractional's 2790 nm wavelength is aggressive enough to produce excellent results, yet predictable enough to deliver a high safety profile.

Mechanism of Action
Pearl Fractional's distinctive wavelength provides the perfect balance of ablation and thermal coagulation.
• 300 micron diameter spots maximize tissue ablation deep in the dermis
• Just the right amount of thermal coagulation controls bleeding
• A balanced approach optimizes patient results, treatment experience and downtime

YSGG Microcolumns
• Deep dermal ablation (> 1 mm) for maximum results in one treatment (1)
• Thermal coagulation reduces operative bleeding (2)
• Controlled thermal damage and minimal necrotic tissue improves healing time (3)
• Fewer complications due to minimal thermal overlap

http://www.cutera.com/product.asp?view=295



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist